Market research
ELTX Elicio Therapeutics Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 16.5
- Dividend yield
- Not available
- Beta
- 1.86
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US28657F1030
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 16.5
- Dividend yield
- Not available
- Beta
- 1.86
About
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the ELTX discussion.
No comments yet
Start a focused discussion about ELTX.